LGALS3 cfDNA methylation in seminal fluid as a novel prostate cancer biomarker outperforming PSA
The Prostate · 2024
DOI: 10.1002/pros.24749 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Prostate, 2024. Verfasst von Irena Abramovic und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Biology, University of Zagreb School of Medicine, Zagreb, Croatia. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Biomarkers, Tumor, DNA Methylation, Prostate-Specific Antigen. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Croatian Science Foundation, Scientific Center of Excellence for Reproductive and Regenerative Medicine, European Regional Development Fund.
Abstract (Originalsprache)
Background
The unmet challenge in prostate cancer (PCa) management is to discriminate it from benign prostate hyperplasia (BPH) due to the lack of specific diagnostic biomarkers. Contemporary research on potential PCa biomarkers is directed toward methylated cell‐free DNA (cfDNA) from liquid biopsies since epigenetic mechanisms are strongly involved in PCa development.
Methods
In the present research, cfDNA methylation of the LGALS3 gene in blood and seminal plasma of PCa and BPH patients was assessed using pyrosequencing, as well as LGALS3 DNA methylation in tissue biopsies. Liquid biopsy samples were taken from patients with clinical suspicion of PCa, who were subsequently divided into two groups, that is, 42 with PCa and 55 with BPH, according to the histopathological analysis.
Results
Statistically significant higher cfDNA methylation of LGALS3 in seminal plasma of BPH than in PCa patients was detected by pyrosequencing. ROC curve analysis showed that it could distinguish PCa and BPH patients with 56.4% sensitivity and 70.4% specificity, while PSA did not differ between the two patient groups. In contrast, there was no statistically significant difference in LGALS3 cfDNA methylation in blood plasma between the two patient groups. In prostate tumor tissue, there was a statistically significant DNA hypermethylation of LGALS3 compared to surrounding nontumor tissue and BPH tissue.
Conclusions
The DNA hypermethylation of the LGALS3 gene represents an event specific to PCa development. In conclusion, LGALS3 cfDNA methylation in seminal fluid discriminates early PCa and BPH presenting itself as a powerful novel PCa biomarker highly outperforming PSA.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Biology, University of Zagreb School of Medicine, Zagreb, Croatia.
- Scientific Group for Research on Epigenetic Biomarkers, University of Zagreb School of Medicine, Zagreb, Croatia.
- Scientific Centre of Excellence for Reproductive & Regenerative Medicine, University of Zagreb School of Medicine, Zagreb, Croatia.
- Department of Urology, University Clinical Hospital Center Sestre Milosrdnice, Zagreb, Croatia.
- Department of Pathology, Cytology and Forensic Medicine, Varazdin General Hospital, Varazdin, Croatia.
- Department of Pathology and Cytology, University Hospital Centre Zagreb, Zagreb, Croatia.
ORCID-Profile: Irena Abramovic
Förderung
- Croatian Science Foundation
- Scientific Center of Excellence for Reproductive and Regenerative Medicine
- European Regional Development Fund
- School of Medicine University of Zagreb
Zitieren
APA
Abramovic, I., Pezelj, I., Dumbovic, L., Skara Abramovic, L., Vodopic, T., Bulimbasic, S., Stimac, G., Bulic-Jakus, F., Kulis, T., Katusic Bojanac, A., Tomas, D., Ulamec, M., & Sincic, N. (2024). LGALS3 cfDNA methylation in seminal fluid as a novel prostate cancer biomarker outperforming PSA. The Prostate. https://doi.org/10.1002/pros.24749
Vancouver
Abramovic I, Pezelj I, Dumbovic L, Skara Abramovic L, Vodopic T, Bulimbasic S, et al. LGALS3 cfDNA methylation in seminal fluid as a novel prostate cancer biomarker outperforming PSA. The Prostate. 2024. doi:10.1002/pros.24749
BibTeX
@article{Abramovic2024,
author = {Abramovic, Irena and Pezelj, Ivan and Dumbovic, Leo and Skara Abramovic, Lucija and Vodopic, Tonci and Bulimbasic, Stela and Stimac, Goran and Bulic-Jakus, Floriana and Kulis, Tomislav and Katusic Bojanac, Ana and Tomas, Davor and Ulamec, Monika and Sincic, Nino},
title = {LGALS3 cfDNA methylation in seminal fluid as a novel prostate cancer biomarker outperforming PSA},
journal = {The Prostate},
year = {2024},
doi = {10.1002/pros.24749}
}
EUVIMED